A group of innovative pharmaceutical enterprises landed on the science and technology innovation board to promote the development of innovative drugs

[pharmaceutical network industry trends] Based on the view of the space of the pharmaceutical industry, the core idea of investment in the pharmaceutical industry - always embrace innovation It is understood that in recent years, with the continuous growth of domestic market demand for innovative drugs and the promotion of a series of national innovative drug reform policies, the domestic innovative drug market has ushered in new opportunities In 2019, domestic regulatory agencies still give positive signals, and more innovative drugs will be listed In this context, China's innovative drugs are ushering in excellent environment and conditions in 2020 In terms of market, talents, scientific research conditions, research basis and other aspects, R & D of innovative drugs has broad fertile ground The author has learned that some innovative pharmaceutical enterprises have recently announced landing on the science and technology innovation board, docking with the capital market, and promoting the development of innovative drugs Pharma (photo source: pharma.com) baiaotai is committed to developing a new generation of innovative drugs and biological similar drugs, landing on the science and Technology Innovation Board Baiaotai biopharmaceutical Co., Ltd (hereinafter referred to as "baiaotai" or "the company") is an innovative biopharmaceutical enterprise focusing on the research and development of innovative drugs and bio similar drugs, and its main research products are bio similar drugs On February 21, biotherapex, an innovative pharmaceutical and biological enterprise, officially launched on the science and technology innovation board The listing of baiaotai has dual significance For the capital market, baiaotai is currently the second unprofitable enterprise holding the fifth set of listing standards, and its smooth listing has reference significance for more unprofitable innovative R & D enterprises to IPO; for the region, baiaotai's listing has also become the fourth scientific and technological innovation board company cultivated by Guangzhou Development Zone of Huangpu District, effectively leading Guangzhou scientific and technological innovation enterprises and capital city Field docking It is understood that baiaotai has the industry-leading antibody discovery and optimization technology, and the advanced platform technology supports its sustainable drug innovation ability and complete drug independent research and development ability The company is committed to developing a new generation of innovative drugs and bio similar drugs for the treatment of tumors, autoimmune diseases, cardiovascular diseases and other major diseases endangering human life or health In the future, based on the existing R & D platform, the company will increase R & D investment, accelerate the upgrading of R & D platform, comprehensively improve the existing R & D equipment conditions and test environment, so as to speed up the R & D Progress of research projects, improve the company's cutting-edge technology development ability and core technology transformation ability, so as to improve the company's core competitiveness Renhui biology is a high-tech enterprise focusing on independent research and development and industrialization of innovative biological drugs in the fields of Endocrinology, cardiovascular and tumor treatment The company's long-term development vision is to continuously innovate and provide patients with "best in class" innovative biological medicine On February 14, Shanghai Stock Exchange newly accepted the listing application of Renhui biological science and technology innovation board Pharmaceutical industry researchers said that Renhui biological transferred to scientific and technological innovation board, and its recognition of the company was mainly based on its achievements in innovative diabetes drugs
According to the prospectus, Renhui bio was approved to be an innovative drug in the field of diabetes in China in December 2016 It is also a human-derived GLP-1 drug and a national class 1 new drug - benaluptide injection (trade name: yishengtai) It has carried out phase III clinical research of bem-014 in the field of weight reduction treatment in the Chinese market and FDA approved clinical research in the United States If it is approved, the drug will be approved Wu is expected to become an innovative drug for overweight / obesity indications in China Zejing pharmaceutical has broken through the scientific innovation board and focused on innovation driven new drug research and development in multiple treatment fields Zejing pharmaceutical is an innovation driven new drug research and development enterprise focusing on tumor, hemorrhage, blood disease, hepatobiliary disease and other treatment fields At present, it is developing 11 innovative drugs and has no products on the market On January 6, Zejing pharmaceutical officially launched its IPO As an unprofitable scientific and technological enterprise, Zejing pharmaceutical has a strong foundation in breaking through the scientific and technological innovation board In the field of small molecule targeted new drugs, many products have submitted listing applications These targeted new drugs have strong competitiveness in their respective treatment fields, and will be expected to bring considerable sales revenue to Zejing pharmaceutical and help it achieve profitability as soon as possible after listing Relevant directors said that the reform and innovation of science and technology innovation board have brought great resources and development assistance to science and technology innovation enterprises, which can make the company really calm down to do scientific research, and the company will also create greater value for the capital market and the whole society Only when we have the hard conditions can we seize this opportunity At present, the product pipeline of Zejing pharmaceutical has 29 research projects of 11 main drugs under research, among which 4 are in phase II / III clinical trials The company expects to complete the phase III clinical trial of donafinil in the first-line treatment of advanced HCC in early 2020 and submit NDA (new drug listing application) in the first quarter of 2020